文献速递外周动脉疾病

八十岁及以上高龄患者因间歇性跛行行下肢血运重建的结局

Outcomes of lower extremity revascularization in octogenarians and nonagenarians for intermittent claudication.
PubMed 文献 · J Vasc Surg · 2023-10-06

基于血管质量倡议(2010-2020)数据,比较年龄≥80岁与<80岁因间歇性跛行行下肢血运重建的结局。共纳入84,210例外周血管介入和10,980例腹股沟下旁路术。高龄组围手术期并发症和1年死亡率更高,1年独立行走比例更低,风险校正后死亡风险仍显著升高。

要点

  • 年龄≥80岁患者行外周血管介入后1年死亡风险较年轻组升高(HR 1.92)。
  • 年龄≥80岁患者行腹股沟下旁路术后1年死亡风险较年轻组升高(HR 1.85)。
  • 高龄患者围手术期并发症更多,1年独立行走比例更低。

核心结论

  • 八十岁及以上高龄患者因间歇性跛行行外周血管介入或腹股沟下旁路术后,围手术期并发症、长期行走障碍、肢体丢失和死亡风险更高。
  • 对高龄间歇性跛行患者进行干预时,应仔细权衡风险与血运重建的预期获益,并应最大化药物和运动治疗。

研究设计与样本

  • 回顾性队列研究,查询血管质量倡议(Vascular Quality Initiative)数据库2010-2020年因间歇性跛行行外周血管介入(PVI)和腹股沟下旁路术(IIB)的病例,比较年龄≥80岁与<80岁患者。
  • 共纳入84,210例PVI(年龄≥80岁占12.1%,<80岁占87.9%)和10,980例IIB(年龄≥80岁占7.4%,<80岁占92.6%)。

主要发现

  • PVI中,年龄≥80岁组更多接受股腘动脉(70.7% vs 58.1%)和膝下动脉(19% vs 9.3%)干预,较少接受髂动脉干预(32.1% vs 48%)(P < .001)。
  • PVI后年龄≥80岁组围手术期血肿(3.5% vs 2.4%)和30天死亡率(0.9% vs 0.4%)更高(P < .001);1年独立行走比例更低(80% vs 91.5%;P < .001)。
  • PVI后年龄≥80岁组1年免于再干预/截肢生存率(81.4% vs 86.8%)、免于截肢生存率(87.1% vs 94.1%)和生存率(92.3% vs 96.8%)均更低(P < .001)。
  • PVI风险校正分析显示,年龄≥80岁与更高的再干预/截肢/死亡(HR 1.22;95%CI 1.1-1.35)、截肢/死亡(HR 1.85;95%CI 1.61-2.13)和死亡(HR 1.92;95%CI 1.66-2.23)风险相关(P < .001)。
  • IIB中,年龄≥80岁组更多以膝下动脉为靶目标(28.4% vs 19.4%),30天死亡率(1.3% vs 0.5%)、肾衰竭(4.1% vs 2.2%)和心脏并发症(5.4% vs 3.1%)更高(P < .001);1年独立行走比例更低(81.7% vs 88.8%;P = .02)。

临床怎么用

  • 作者认为,对高龄间歇性跛行患者进行干预时,应仔细权衡风险与血运重建的预期获益。
  • 作者认为,应最大化该人群的药物治疗和运动治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Revascularization for intermittent claudication (IC) due to infrainguinal peripheral arterial disease (PAD) is dependent on durability and expected benefit. We aimed to assess outcomes for IC interventions in octogenarians and nonagenarians (age ≥80 years) and those younger than 80 years (age <80 years). METHODS: The Vascular Quality Initiative was queried (2010-2020) for peripheral vascular interventions (PVIs) and infrainguinal bypasses (IIBs) performed to treat IC. Baseline characteristics, procedural details, and outcomes were analyzed (comparing age ≥80 years and age <80 years). RESULTS: There were 84,210 PVIs (12.1% age ≥80 years and 87.9% age <80 years) and 10,980 IIBs (7.4% age ≥80 years and 92.6% age <80 years) for IC. For PVI, patients aged ≥80 years more often underwent femoropopliteal (70.7% vs 58.1%) and infrapopliteal (19% vs 9.3%) interventions, and less often iliac interventions (32.1% vs 48%) (P < .001 for all). Patients aged ≥80 years had more perioperative hematomas (3.5% vs 2.4%) and 30-day mortality (0.9% vs 0.4%) (P < .001). At 1-year post-intervention, the age ≥80 years cohort had fewer independently ambulatory patients (80% vs 91.5%; P < .001). Kaplan-Meier analysis showed patients aged ≥80 years had lower reintervention/amputation-free survival (81.4% vs 86.8%), amputation-free survival (87.1% vs 94.1%), and survival (92.3% vs 96.8%) (P < .001) at 1-year after PVI. Risk adjusted analysis showed that age ≥80 years was associated with higher reintervention/amputation/death (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.1-1.35), amputation/death (HR, 1.85; 95% CI, 1.61-2.13), and mortality (HR, 1.92; 95% CI, 1.66-2.23) (P < .001 for all) for PVI. For IIB, patients aged ≥80 years more often had an infrapopliteal target (28.4% vs 19.4%) and had higher 30-day mortality (1.3% vs 0.5%), renal failure (4.1% vs 2.2%), and cardiac complications (5.4% vs 3.1%) (P < .001). At 1 year, the age ≥80 years group had fewer independently ambulatory patients (81.7% vs 88.8%; P = .02). Kaplan-Meier analysis showed that the age ≥80 years cohort had lower reintervention/amputation-free survival (75.7% vs 81.5%), amputation-free survival (86.9% vs 93.9%), and survival (90.4% vs 96.5%) (P < .001 for all). Risk-adjusted analysis showed age ≥80 years was associated with higher amputation/death (HR, 1.68; 95% CI, 1.1-2.54; P = .015) and mortality (HR, 1.85; 95% CI, 1.16-2.93; P = .009), but not reintervention/amputation/death (HR, 1.1; 95% CI, 0.85-1.44; P = .47) after IIB. CONCLUSIONS: Octogenarians and nonagenarians have greater perioperative morbidity and long-term ambulatory impairment, limb loss, and mortality after PVI and IIB for claudication. Risks of intervention on elderly patients with claudication should be carefully weighed against the perceived benefits of revascularization. Medical and exercise therapy efforts should be maximized in this population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Haqqani MH, Kester LP, Lin B, et al. Outcomes of lower extremity revascularization in octogenarians and nonagenarians for intermittent claudication. J Vasc Surg. 2023. PMID: 37804952. doi:10.1016/j.jvs.2023.08.112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。